Stay updated on Pralsetinib in RET+ Cancer Clinical Trial
Sign up to get notified when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.

Latest updates to the Pralsetinib in RET+ Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check22 days agoChange DetectedPage now reflects a new release (v3.2.0) and an urgent operating-status notice due to funding gaps; an older resource topic (Medullary thyroid carcinoma) is removed.SummaryDifference1%

- Check29 days agoChange DetectedCore term updated: 'Medullary thyroid gland carcinoma' → 'Medullary thyroid carcinoma'; page version updated from v3.0.2 to v3.1.0.SummaryDifference0.0%

- Check43 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2; the 'Back to Top' link was removed.SummaryDifference0.1%

- Check50 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.1%

- Check58 days agoChange DetectedThe webpage has been updated to include new facility names and locations, as well as additional resources related to genetic and rare diseases, particularly focusing on various types of cancers. Notably, several previous entries have been removed, including some cancer-related topics and specific location details.SummaryDifference7%

- Check72 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%

Stay in the know with updates to Pralsetinib in RET+ Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.